Tetra Bio-Pharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Guy Chamberland Master Herbal
- Full Time Employees
- 33
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2316 St. Joseph Boulevard Orléans ON Canada K1C 1E8
- IPO Date
- Sep 25, 2012
- Website
- tetrabiopharma.com
- Similar Companies
- Business
- Tetra Bio-Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of plant-derived cannabinoid-based medications and therapeutics. The company’s main products and services include proprietary cannabinoid drug delivery platforms; pharmaceutical-grade medical cannabis formulations; proprietary analgesic, anti-inflammatory, and anti-cancer cannabinoid products; research and development services focused on cannabinoid science; and licensing of intellectual property related to cannabinoid therapeutics. Tetra Bio-Pharma operates across North America and Europe, targeting markets including patients with chronic pain, oncology, and other medical conditions where cannabinoid treatments are applicable. Founded in 2012 and headquartered in Ontario, Canada, the company leverages its vertically integrated capabilities comprising proprietary extraction, formulation, and pharmaceutical manufacturing. In the past 1-2 years, Tetra Bio-Pharma has undertaken significant operational expansions, including strategic partnerships with pharmaceutical companies to accelerate the commercialization of cannabinoid-based drugs and new product launches targeting chronic pain and cancer-related symptom management. The company has expanded its research pipeline with novel drug candidates and enhanced its manufacturing capacity to support growing demand. Additionally, Tetra Bio-Pharma has increasingly focused on gaining regulatory approvals and entering new geographic markets within Europe and North America, reflecting a strategic shift towards becoming a fully integrated biopharmaceutical entity in the cannabinoid pharmaceutical sector. The company is listed publicly under the ticker TBPMF and maintains a focus on advancing cannabinoid science through clinical trials and regulatory approvals, positioning itself within the biopharma and medical cannabis industries. Its subsidiaries support specialized functions including research, pharmaceutical development, and commercial supply chain logistics. Tetra Bio-Pharma’s comprehensive approach encompasses drug research, proprietary formulation technologies, and commercialization strategies aimed at improving patient outcomes through cannabinoid-based therapies.
Tetra Bio-Pharma & Avicanna Enter Into Strategic Partnership
Tetra Bio-Pharma: Positive Clinical Data From Both Phase 2 Clinical Trials Of QIXLEEF For Cancer Pain
Tetra Bio-Pharma advancing breakthrough pain drug QIXLEEF to late clinical development stage
Tetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™
Tetra Bio-Pharma says its first cannabinoid-derived medicine REDUVO is a ‘major milestone' as it gears up to launch it
Tetra Bio-Pharma draws positive Scientific Advice Assessment report for its cannabinoid-based drug candidate QIXLEEF
Tetra Bio-Pharma receives positive Scientific Advice Assessment report for its cannabinoid-based drug candidate QIXLEEF
Tetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™
Tetra Bio-Pharma files a PCT patent application for 'Cannabis Plant Residue and Use Thereof'
Tetra Bio-Pharma Files PCT Patent Application for Cannabis Plant Residue
Tetra Bio-Pharma welcomes Christine Caron as a patient partner in its sepsis research
Tetra Bio-Pharma Engages Christine Caron as Patient Partner
Tetra Bio-Pharma puts QIXLEEF study on the fast track with introduction of three more oral pain relief treatments for comparison
Tetra Bio-Pharma put QIXLEEF study on the fast track with introduction of three more oral pain relief treatments for comparison
Tetra Bio-Pharma Accelerates REBORN1© Trial
Tetra Bio-Pharma says research finds new antiviral properties in its drug candidate ARDS-003
Significant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003
Tetra Bio-Pharma progressing fast as it advances coronavirus drug candidate ARDS-003 to human trials
Tetra Bio-Pharma says Health Canada has accepted its NDS for REDUVO to treat chemotherapy-induced nausea and vomiting
Tetra Bio-Pharma says Health Canada has accepted its NDS for REDUVO™ for chemotherapy-induced nausea and vomiting